Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Turning the tide on
cancer drug costs
The increase in the median monthly cost
of cancer drugs in the US since 19902
©2015E...
Upcoming SlideShare
Loading in …5
×
Upcoming SlideShare
How do we see the healthcare's digital future and its impact on our lives?
Next
Download to read offline and view in fullscreen.

48

Share

Download to read offline

Turning the tide on cancer drug costs

Download to read offline

Summary: At The Economist’s War on Cancer 2015 event on 20 October 2015 (http://www.economist.com/events-conferences/emea/war-cancer-london), EY’s Silvia Ondategui-Parra joined the panel discussion “The patient/payer debate—balancing clinical need and affordability.” The panel explored the ongoing tension between the soaring cost of cancer drugs and governments’ ability to fund them and raised the question, do we need an entirely new pricing model? This EY infographic was developed to highlight some of the key trends driving the debate.

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all

Turning the tide on cancer drug costs

  1. 1. Turning the tide on cancer drug costs The increase in the median monthly cost of cancer drugs in the US since 19902 ©2015EYGMLimited.AllRightsReserved.EYGno.FN0236.EDNone 1 A rising tide of new cancer drugs helps patients. These contracts are complex to build, but can provide a strong foundation for patient access. To hold back the tide of oncology drug costs, payers …3 ... experiment with new models US payers test indication-specific pricing, taking advantage of four new drug value tools. Since 2006, NICE has issued negative recommendations for of the cancer drugs reviewed.3 ... limit patient access Innovative risk-sharing agreements are another way to turn the tide.4 of the contracts are for cancer drugs.4 65%The number of risk-sharing contracts created in the UK and Italy since 2006 90 Sources: 1 U.S. Food & Drug Administration, Memorial Sloan Kettering Cancer Center, Decision Resources. 2 Peter Bach, Memorial Sloan Kettering Cancer Center, Center for Health Policy and Outcomes, "Price and Value of Cancer Drug," 2015. 3 EY, National Institute for Health and Care Excellence (NICE). 4 Van de Vooren, et al., “Market-access agreements for anti-cancer drugs,” J R Soc Med (108): 166–170, 2015. Since 1990, new cancer drugs have been approved in the US. 117 50Another could reach the market by 2020.1 $41% >700% 2 This wave of innovation could drown payers.
  • hennieswanepoel927

    Jul. 27, 2021
  • drrichardselden

    Mar. 3, 2021
  • DavidShorenstein

    Dec. 15, 2020
  • Thinkerkadir

    Oct. 31, 2020
  • MelissaDuarte20

    Feb. 8, 2020
  • omaruriel

    Jan. 28, 2020
  • VishalChavan86

    Sep. 25, 2019
  • guidaateia

    Aug. 18, 2019
  • DrLoriGoreGreen

    Aug. 14, 2019
  • RobertVatersMBA

    Jan. 30, 2019
  • AnthonyKopiecki

    Dec. 4, 2018
  • LindaPalson

    Oct. 22, 2018
  • AlexLucio1

    Sep. 10, 2018
  • ToddBernerMD

    Aug. 15, 2018
  • drrandynordyke

    Mar. 23, 2018
  • GilTepperMDFACS

    Mar. 1, 2018
  • ZeeshanHoodbhoy

    Feb. 22, 2018
  • yicnoryvargas

    Oct. 4, 2017
  • WilliamAspelin

    Aug. 29, 2017
  • r16l68

    Feb. 2, 2017

Summary: At The Economist’s War on Cancer 2015 event on 20 October 2015 (http://www.economist.com/events-conferences/emea/war-cancer-london), EY’s Silvia Ondategui-Parra joined the panel discussion “The patient/payer debate—balancing clinical need and affordability.” The panel explored the ongoing tension between the soaring cost of cancer drugs and governments’ ability to fund them and raised the question, do we need an entirely new pricing model? This EY infographic was developed to highlight some of the key trends driving the debate.

Views

Total views

7,215

On Slideshare

0

From embeds

0

Number of embeds

78

Actions

Downloads

103

Shares

0

Comments

0

Likes

48

×